First human double hand transplantation: efficacy of a conventional immunosuppressive protocol.
Based on the results achieved in single human hand transplantations, we decided to perform the first double hand transplantation with a conventional immunosuppressive protocol in a patient with a high potential for functional recovery. Two years after transplantation the efficacy and the safety of this immunosuppressive protocol are evaluated. The recipient was a 33-yr-old man suffering from a traumatic amputation of both hands in 1996. Five HLA-A, -B, and -DR mismatches were present with the donor; T and B cell cross-match was negative. Immunosuppressive protocol included tacrolimus, prednisone, mycophenolate mofetil and, for induction, antithymocyte globulins and then anti CD25 monoclonal antibody. Reconstitution of lymphocyte populations proceeded normally. Neither anti-HLA antibodies nor chimerism in peripheral blood were detected. Two episodes of acute rejection characterized by maculopapular lesions occurred on days 53 and 82 after transplantation. Skin biopsies revealed a dermal lymphocytic infiltrate. Both episodes were completely and rapidly reversed by topical clobetasol and increased systemic corticosteroid therapy. The only side-effects related to treatment were reversible serum sickness and hyperglycemia. No infectious complications and malignancies occurred. No signs of graft-versus-host disease have been detected. This case of double hand transplantation shows that conventional immunosuppression is effective and safe to ensure survival and functional recovery of the grafted limb.
Petruzzo
Palmina
P
Service de Chirurgie de Transplantation, Hôpital Edouard Herriot, Lyon, France.
Revillard
Jean Pierre
JP
Kanitakis
Jean
J
Lanzetta
Marco
M
Hakim
Nadey S
NS
Lefrançois
Nicole
N
Owen
Earl
E
Dubernard
Jean Michel
JM
D000328:Adult; D000673:Amputation, Traumatic / Q000601:surgery; D006084:Graft Rejection / Q000188:drug therapy; D006085:Graft Survival; D006230:Hand Injuries / Q000601:surgery; D063987:Hand Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D016896:Treatment Outcome
D007166:Immunosuppressive Agents